Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Eric Andrew Collisson

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2829-355X; OpenAlex author ID A5101642291. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
49
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 9

  1. Alliance A022106: A Phase II/III Trial of Nab-Paclitaxel and Gemcitabine ± Cisplatin as Second-Line Treatment for BRCA1/2 or PALB2 Mutant Metastatic Pancreatic… Co-author DOI 10.1200/oa-25-00099↗
  2. Pancreatic Cancer Action Network's SPARK: A Cloud-Based Patient Health Data and Analytics Platform for Pancreatic Cancer. Co-author DOI 10.1200/cci.23.00119↗
  3. Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamanetworkopen.2022.16199↗
  4. The Additional Diagnostic Benefit of Pancreatic Cancer Molecular Profiling After Germline Testing. Co-author DOI 10.1097/mpa.0000000000002021↗
  5. Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. Co-author DOI 10.1200/po.20.00494↗
  6. Molecular subtypes of pancreatic cancer. Co-author DOI 10.1038/s41575-019-0109-y↗
  7. Pancreatic Cancer: Progress and Challenges in a Rapidly Moving Field. Co-author DOI 10.1158/0008-5472.can-16-2452↗
  8. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Tri… Co-author DOI 10.1001/jamasurg.2016.1137↗
  9. Blinded by the light: molecular imaging in pancreatic adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-10-2825↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrew H. Ko · 2 shared papers, 2022–2025 · strength 0.40
  2. Kenneth P. Olive · 2 shared papers, 2017–2025 · strength 0.37
  3. Eileen Mary O'Reilly · 2 shared papers, 2021–2025 · strength 0.34
  4. Margaret A. Tempero · 2 shared papers, 2011–2022 · strength 0.23
  5. Mike Cusnir · 1 shared paper, 2025 · strength 0.22
  6. Raymond Couric Wadlow · 1 shared paper, 2025 · strength 0.22
  7. Rafael Winograd · 1 shared paper, 2025 · strength 0.22
  8. Erica S. Tsang · 1 shared paper, 2025 · strength 0.22
  9. Gregory P. Botta · 1 shared paper, 2025 · strength 0.22
  10. Avital Klein-Brill · 1 shared paper, 2022 · strength 0.20
  11. Dvir Aran · 1 shared paper, 2022 · strength 0.20
  12. Julia C. Carnevale · 1 shared paper, 2022 · strength 0.17
  13. Pelin Cinar · 1 shared paper, 2022 · strength 0.17
  14. Evan Justin Walker · 1 shared paper, 2022 · strength 0.17
  15. Kevin P. White · 1 shared paper, 2024 · strength 0.17
  16. Kawther Abdilleh · 1 shared paper, 2024 · strength 0.17
  17. Anirban Maitra · 1 shared paper, 2024 · strength 0.17
  18. Sudheer Doss · 1 shared paper, 2024 · strength 0.17
  19. Lynn McCormick Matrisian · 1 shared paper, 2024 · strength 0.17
  20. Peter J. Bailey · 1 shared paper, 2019 · strength 0.14
  21. David Kuang-Fu Chang · 1 shared paper, 2019 · strength 0.14
  22. Andrew Victor Biankin · 1 shared paper, 2019 · strength 0.14
  23. Timothy Lewis Cannon · 1 shared paper, 2021 · strength 0.11
  24. Emanuel F. Petricoin · 1 shared paper, 2021 · strength 0.11
  25. Andrew Eugene Hendifar · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.